MENU
+Compare
DVAX
Stock ticker: NASDAQ
AS OF
Jan 17 closing price
Price
$12.45
Change
+$0.06 (+0.48%)
Capitalization
1.62B

DVAX Dynavax Technologies Corp Forecast, Technical & Fundamental Analysis

a developer of novel products to prevent and treat infectious diseases

DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for DVAX with price predictions
Jan 08, 2025

DVAX's Stochastic Oscillator entering oversold zone

The Stochastic Oscillator for DVAX moved into oversold territory on January 08, 2025. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DVAX advanced for three days, in of 278 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on January 08, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on DVAX as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

DVAX moved below its 50-day moving average on January 08, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DVAX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. DVAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.641) is normal, around the industry mean (58.527). P/E Ratio (31.634) is within average values for comparable stocks, (90.460). DVAX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.947). Dividend Yield (0.000) settles around the average of (0.122) among similar stocks. P/S Ratio (6.974) is also within normal values, averaging (19.547).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

DVAX is expected to report earnings to fall 66.00% to 4 cents per share on February 20

Dynavax Technologies Corp DVAX Stock Earnings Reports
Q4'24
Est.
$0.04
Q3'24
Est.
$0.12
Q2'24
Beat
by $0.02
Q1'24
Missed
by $0.05
Q4'23
Beat
by $0.03
The last earnings report on November 07 showed earnings per share of 11 cents, meeting the estimate of 11 cents. With 1.25M shares outstanding, the current market capitalization sits at 1.62B.
A.I. Advisor
published General Information

General Information

a developer of novel products to prevent and treat infectious diseases

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Biotechnology
Address
2100 Powell Street
Phone
+1 510 848-5100
Employees
408
Web
https://www.dynavax.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TROIX12.700.06
+0.47%
T. Rowe Price Overseas Stock I
SZCRX52.590.06
+0.11%
DWS Small Cap Core R6
JHARX10.070.01
+0.10%
JHancock Multi-Asset Absolute Return R2
GACCX24.96N/A
N/A
Gabelli Global Rising Income and Div C
GIRMX22.85N/A
N/A
Goldman Sachs Emerging Markets Eq Inv

DVAX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, DVAX has been loosely correlated with ACET. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if DVAX jumps, then ACET could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DVAX
1D Price
Change %
DVAX100%
+0.48%
ACET - DVAX
39%
Loosely correlated
-1.22%
SNDL - DVAX
35%
Loosely correlated
-1.11%
SUPN - DVAX
33%
Loosely correlated
-0.34%
AMPH - DVAX
29%
Poorly correlated
+0.11%
ETON - DVAX
27%
Poorly correlated
+0.91%
More